NCT00617877已完成不适用
Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 800
- 主要终点
- Blood pressure reduction with reference to genetic polymorphisms.
研究概览
简要总结
The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Both gender less than 60 years old, with mild-moderate hypertension (SBP greater than and DBP equal or greater than 90 mmhg, BP < 180/110)
- •Never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit
- •Patient in therapeutic wash out for 6 months
- •Patient is asymptomatic, absence of significant concomitant diseases, except for non-familial hypercholesterolemia, absence of systemic diseases
- •Women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estro-progestagen agents but who use another safe contraceptive method
- •BMI < 30 for men and < 28 for women
排除标准
- •Secondary or malignant hypertension, Na <130 mmol/l, K >5,5 mmol/l, or < 3,0 mmol/l
- •Cardiac disease such as ischemic, HF, arrhythmia, cardiac surgery
- •Pregnant, breast feeding
- •History of nephropathy, metabolic disease, liver disease
- •Alcohol or drug abuse
- •History of angioedema
- •Has a known hypersensibility to study drug(s)
研究组 & 干预措施
1
Experimental
Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
干预措施: losartan potassium (Drug)
结局指标
主要结局
Blood pressure reduction with reference to genetic polymorphisms.
时间窗: Over 1 Year
次要结局
未报告次要终点
研究者
相似试验
Unknown
不适用
PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-MetabolitesHypertensionNCT00561327German Heart Institute
已完成
4 期
Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B-Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin 2 Type 1 Receptor Antagonist Based TherapyHypertensionJPRN-UMIN000007101Southern Heart Conference200
已完成
4 期
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)HypertensionNCT00140959Organon and Co120
终止
4 期
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1HypertensionNCT03738878Vanderbilt University Medical Center4
已完成
4 期
Effect of Termisartan or Losartan in Hypertensive Diabetic Patients with MacroalbumiuriaJPRN-UMIN000000797Saitama Medical University100